This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. tied) Insider , $500M, digital marketing: Marketing tech platform Insider raised a $500 million Series E led by General Atlantic to fund its expansion in the U.S.
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
In fact, it took $200 million or more to make the list last month, as defense tech and cybersecurity led the way. Eikon Therapeutics , $351M, biotech: Eikon Therapeutics raised one of the biggest biotech rounds thus far in 2025. Harvey develops AI tools that help legal pros with research, document review and contract analysis.
As Italy reinstates many COVID-19 restrictions, the country’s tech ecosystem is watching and waiting to see what the wider effects of the emergency will be. Italy’s ecosystem for tech venture capital and startups has been in development for years and has made decent strides in the last decade.
To a great degree, the largest rounds of the year went to a handful of AI companies working on large language models and underlying technologies to scale them. While the Boston startup scene is famous for biotech and deeptech talent, the city has lagged other hubs in creation of ultra-high-valuation AI unicorns.
With the constant advancements in technology and research, businesses in this sector require leaders who possess a deep understanding of the scientific landscape and the business acumen to drive growth and innovation. The life sciences industry is known for its unique challenges in recruiting and hiring.
Last year, round sizes for climate tech startups quadrupled, with more than 600 investments totaling over $40 billion. What is your climate tech investment thesis in H1 2022? Which technologies are you paying attention to right now? electric scooters, replaceable battery technologies) generate a high volume of e-waste.
Due to its safer formula, Howler can be used as the last spray in the program, and its differentiator is a shorter re-entry period — farmers can spray in the morning and be able to go back out in the field in the afternoon. The company saw 10x sales growth in 2020, Uknes told TechCrunch.
The hearing loss market has long been dominated by a handful of legacy players with little incentive to innovate due to outdated regulations and social stigma. On Monday, the FDA announced that hearing aids and other hearing technology can now be sold over the counter. But a new ruling from the U.S.
Venture money wasnt concentrated in just one sector, as VCs invested in everything from artificial intelligence to biotech to energy. The Norwalk, Connecticut-based firm did not disclose investor names, instead saying it came from a private investor whose portfolio focuses on global technology and real estate investments.
That increase was due in large part to U.S. The most valuable new 2024 unicorn company from China is Huawei Technologies smart car subsidiary Yinwang Smart Technology , valued at $16 billion. Healthcare and biotech was the third-highest sector for new unicorns with nine companies. leadership in AI.
Enterprise tech and AI Cerebras Systems : Yes, this one is kind of cheating. national security review on UAE-based G42 ‘s minority investment in the AI chipmaker. Gen Teare Health and biotech Hinge Health : This is another IPO prediction where were not exactly going out on a limb (pun intended in this case).
Q4 push The higher total in 2024 was due to a big push in Q4 which saw the highest funding total since the downturn in Q3 2022. Large early-stage rounds went to data centers, renewable energy, AI, robotics and biotech. Technology growth is a private-equity round raised by a company that has previously raised a venture round. (So
Sure, duediligence matters in the investment process, but lying about your capabilities can undercut the founder-investor relationship — and in extreme cases, to the detriment of the larger, global startup market. Soon she was the CEO of a company with a $10 billion valuation, but it turned out that the technology didn’t work.
Now, certain industries are emerging as potential areas where New Zealand can win in the tech space. Deep tech, medtech/biotech, climate tech, and crypto and blockchain are all areas that investors say they’re either actively investing in or watching for signs of scale. New Zealanders make really good founders.
Now tech companies across industries are poised for an even better year, according to more than a dozen investors we talked to in the country. Other investors felt that a broader range of industries, like fintech and biotech, would eventually produce the biggest companies in the country. Oh, and one more thing.
5 investors discuss Boston’s resilient tech ecosystem Boston’s university-to-startup pipeline defies downturn to grow and diversify In order to build a startup culture, a city or region needs some key elements in place – like an innovation engine to drive startup ideas. It also has a long history of innovation and a rich tech legacy.
“We seek out exceptional founding teams whose business plan is centered on the strategic utilization of technology to gain a competitive advantage. The technology sector has faced some short- to mid-term pressure globally due to recent market adjustments. We don’t limit ourselves to any specific sector,” Kazah said.
Zero-based budgeting: A proven framework for extending runway 5 strategies for biotech startups to outlast a market downturn Image Credits: Getty Images Spinning up a biotech company is a massive undertaking. “The best founders look for a framework to strategically cut burn while keeping their startup’s value drivers functioning.”
We featured generative AI companies five years before the popular investors took notice and climate tech 2.0 We’re seeing input/output startups that want to rewrite the rules of recycling and purification with new tech. It’s deep tech but actionable. Silver tech – Life expectancy is on the rise and the U.S.
Nerdio , $500M, information technology: IT professionals are stretched pretty thin these days, so it makes sense that a company that helps automate some of their work could raise big. Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers.
It speaks to the speed with which genetics has permeated our lives, but despite massive improvements to the technology, the process can still be a bit clunky in the lab. What I noticed was that the existing technologies for moving, mixing and heating fluids were archaic,” he said. “I And that sample has to get prepped the right way.
“InstaDeep happened to be quite different from other companies in our pipeline as they were actually into deep tech versus applying technology to a certain sector, where basically, you become an operator in that sector. And it was also interesting, especially in Africa, where such companies are quite rare.
“We added fermentation/biotechtechnologies to enhance taste and texture,” wrote CEO and co-founder Christoph Jenny in an email to TechCrunch. is still a question mark due to COVID-19 restrictions on travel. Over time the process has improved as well.
He believes that the tech ecosystem has matured quite a lot in France over the past ten years. France could become a leading market when it comes to sustainability-focused and impact startups due to local and European regulation, innovation and talent looking for opportunities in this ecosystem.
At N2Growth, we approach the healthcare leadership market with a nuanced lens, drawing on decades of industry experience to ensure that leaders possess the necessary technical expertise and the resilience, strategic insight, and emotional intelligence essential for inspiring teams and shaping the future of patient care.
AI, biotech, space tech and cybersecurity also saw good-sized raises. Then, late last year, Cruise suspended its self-driving taxi program across the country after losing its permit to operate in San Francisco due to an incident with a pedestrian. Alzheon , $100M, biotech: Alzheon was the next biotech to raise big this week.
The biggest was in New York-based mortgage servicing platform Valon Technologies ’ $100 million Series C led by WestCap. It also took part in the $135 million Series D for San Francisco-based EvenUp , a legal tech startup creating artificial intelligence products for the personal injury sector. -based startups. based startups.
He met Kim, a user experience expert, whose family owns a pharmacy, and wanted to bring technology into the industry. The pharmacy industry is changing a lot, and technology allows us to personalize the care and experience for the veterinarian, pet parent and the pet,” Kim said. We kept that in mind when starting Mixlab.
When the timing was right, Chavarin honed her skills to do training and coaching work and eventually got her first taste of technology as a member of Synchrony’s intelligent virtual assistant (IVA) team, writing human responses to the text-based questions posed to chatbots.
Meatable has a long road ahead of it, because, as Gates acknowledged in his interview with MIT TechnologyReview (ed. These products don’t get at the full potential for cellular technology according to Daan Luining, Meatable’s chief technology officer. ” For Meatable right now, price remains an issue.
Research on psychedelics was stalled for decades due to DEA scheduling, but capabilities in the fields of pharmacology and medicinal chemistry advanced significantly during this “dark age.” Most ancillary services and technology will not take off until drugs commercialize, so we see few near-term opportunities in other verticals anyway.
In 2020, Scottish startups collectively raised £345 million, according to Tech Nation, and with nearly 2,500 startups, it has the highest number of budding tech companies outside London. However, the city’s tech scene is apparently lackluster when it comes to legal tech, blockchain and consumer-facing technology.
Sorcero announced Thursday a $10 million Series A round of funding to continue scaling its medical and technical language intelligence platform. and Cambridge, Massachusetts, sees increased demand for its advanced analytics from life sciences and technical companies.
OK, with that, here’s what I think will happen next year: the return to in-person, five-day work weeks for tech workers. Then, this year, the Great Resignation became the Great Reset, as employers fired large percentages of their staff due to changing macroeconomic conditions. The impact of hype with Clubhouse’s Paul Davison.
Normally, a CCO develops ideas about what the market needs and communicates them to a design team, which produces sketches to then be reviewed by the CCO. As the technology exhausts its honeymoon period, and companies in all industries find new ways of using it to get ahead of the competition, a new race is on.
While the IPO market wasn’t especially active, we did see a handful of public offerings, predominantly in the biotech sector. billion went to late-stage and technology growth deals in Q3 of 2024. Below, we chart both round counts and total investment for late-stage and technology growth deals over the past five quarters.
The world’s labs are under pressure to do more tests and process more materials, not just due to COVID but from the growing biotech and drug development sectors — and automation is the sure path forwards. the discovery and cultivation of purpose-built microbes).
Serial Kenyan tech entrepreneur Mike Macharia has spent the last two decades helping enterprises like East Africa’s biggest telco Safaricom to create infrastructure that bolsters their growth. But I had never thought of building tech for us (the masses). CarePoint raises $10M to spread healthcare tech across Africa.
UVC lights had a brief moment of fame in mid-2020 for several reasons: they seemed like powerful ways to disinfect communal spaces, and there were certain incentives for companies to apply tech-based solutions to COVID-19. . Amid pandemic, returning to offices remains an open question for tech leaders.
Sunny Kumar, MD, MBA is a partner at GSR Ventures, an early-stage venture capital firm focused on healthcare technology with more than $3.5 Neurodegenerative disease is a major target for digital biomarker development due to a lack of easily accessible indicators that can help providers diagnose and manage these conditions.
” No hard feelings — the tech was largely notional then, he admitted — but since that time the team has continued its work, raised some money , and what was a promising if not well supported thesis then has turned into one backed by firsthand data and clinical outcomes. But ultimately it’s still targeted physical therapy.
Once samples are scanned in the lab, they could be reviewed by hematologists working from anywhere. For instance, some papers argue, the manual review of samples doesn’t often add much to doctors’ diagnostic dataset. You can zoom around in one of the images here. Image Credits: Scopio.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content